GLP-1 weight regain after stopping: what the data says

What did @lauren.reid68 actually say?

Here is the uncomfortable truth about this video: the transcript and the caption are completely disconnected. The caption makes specific medical claims about GLP-1 discontinuation, including a figure of "0.8kg per month" weight regain and an "8,000 real patients" study showing stable weight for over a year. The actual spoken transcript, however, is song lyrics or spoken word poetry with zero medical content. So we are fact-checking the caption claims, because that is all there is to fact-check.

The caption states that research shows people regain roughly 0.8kg per month after stopping weight loss medication, and then pivots to claim that a large real-world cohort of 8,000 patients mostly maintained their weight for over a year. The caption cuts off mid-sentence, so the full argument is never made. That missing context matters a lot here.

Does the science back this up?

The 0.8kg-per-month regain figure is in the right ballpark, but the 8,000-patient stability claim is where things get murky. The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) found participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide, which works out to roughly 0.7-1.0kg per month depending on baseline loss. That part checks out.

The 8,000-patient long-term stability claim is harder to verify. A 2023 real-world analysis published in Obesity (Ghusn et al., 2023) tracked GLP-1 users across clinical settings, but the figures cited in the caption do not cleanly match any single published cohort I can identify. Some retrospective analyses have shown subgroups maintaining weight, but those tend to involve patients who stayed on medication or made significant lifestyle changes, not people who simply stopped.

• Wilding et al., 2022 (NEJM): weight regain of ~6.9% body weight in year after stopping semaglutide
• Ghusn et al., 2023 (Obesity): real-world GLP-1 outcomes varied significantly by adherence and follow-up duration
• Davies et al., 2021 (Lancet): stopping liraglutide showed similar rebound patterns

What did they get wrong (or right)?

The 0.8kg monthly regain figure is a reasonable approximation of published data. Credit where it is due. But the claim that "most kept their weight stable for over a year" after stopping needs serious scrutiny. Most of the available evidence points in the opposite direction. The dominant finding in discontinuation research is meaningful weight regain, not stability.

If a large real-world dataset does show stability in a subset, the explanation almost certainly involves continued behavioral support, dietary change, or unreported medication use, not something inherent about the drug's lasting effects. The caption implies that some unnamed differentiating factor explains stability, but then cuts off before naming it. That is not informative, that is a cliffhanger designed to drive engagement. Presenting a cherry-picked subgroup result as "what actually happens" to 8,000 patients is misleading framing, even if the underlying number exists somewhere.

The video also has a more basic problem: the spoken content is entirely unrelated to the claims in the caption. Viewers reading the caption are getting a different message than anyone listening to the audio.

What should you actually know?

GLP-1 receptor agonists like semaglutide and tirzepatide work largely while you are taking them. The biology is not subtle on this point. When you stop, appetite-regulating hormones shift back toward baseline for most people, and weight tends to follow. The STEP 1 extension data is the clearest long-term evidence we have, and it shows substantial regain within 12 months for most participants who stopped semaglutide.

This does not mean everyone regains all their weight, or that the medications are not worth using. It means they are likely long-term or indefinite treatments for many people, similar to how you would think about blood pressure medication. That framing matters for informed decision-making.

What actually predicts better outcomes after stopping? The research points to a few things: sustained dietary habit changes made during the treatment period, continued physical activity, and in some cases structured follow-up support. No single factor guarantees stability, and no one should stop their medication based on a TikTok caption that cuts off mid-sentence.

• Do not stop GLP-1 medication without talking to your prescriber
• Weight regain after stopping is common and not a personal failure
• Real-world outcomes vary significantly based on how long someone was on medication and what else changed during treatment

Our verdict

The monthly regain estimate is defensible. The broad claim that most of 8,000 patients stayed stable after stopping is either misrepresented, unsourced, or describing a specific subgroup in a way that misleads viewers about typical outcomes. The video structure itself, where the spoken content is completely unrelated to the medical caption, is a format that should make any viewer skeptical about whether the creator has real command of the topic they are posting about.